Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies

Reuters

Sep 10

Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies

Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566467256"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566467256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566467256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566467256","market":"fut","top_or_hot":-1,"title":"Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 06:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL5ywMLf:1","article_id":"2566467256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566467256","pubTimestamp":1757455411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.Discla","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc.","BK4082":"医疗保健设备"},"translate_title":"Vivani Medical Inc.推出创新肥胖治疗和市场扩张策略演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"Vivani Medical Inc. Unveils Presentation on Innovative Obesity Treatment and Market Expansion Strategies\n    \n\n        Vivani Medical Inc. recently held an investor presentation discussing its strategic approach to the evolving obesity market. The company highlighted the potential of a differentiated route of administration, offering a guaranteed-adherence option to improve patient outcomes and access untapped market segments. Currently, over 50 clinical-stage injectables or orals for obesity are in development, with Vivani's unique clinical-stage subdermal implant standing out as a distinctive option. The presentation emphasized the NanoPortal™ technology, which promises convenient and stable drug delivery, potentially reducing side effects and offering pricing flexibility. Vivani's clinical program is progressing, with the LIBERATE-1 study meeting its primary safety and device performance objectives. The GLP-1 market is projected to grow significantly, with Vivani poised to address unmet needs through its innovative product candidates. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}